Millennium Management LLC Cuts Position in Turnstone Biologics Corp. (NASDAQ:TSBX)

Millennium Management LLC cut its holdings in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) by 28.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,744 shares of the company’s stock after selling 29,284 shares during the period. Millennium Management LLC owned about 0.32% of Turnstone Biologics worth $37,000 as of its most recent SEC filing.

Separately, Takeda Pharmaceutical Co. Ltd. acquired a new stake in Turnstone Biologics in the fourth quarter valued at approximately $448,000. Institutional investors own 52.51% of the company’s stock.

Turnstone Biologics Trading Down 3.8%

Shares of TSBX stock opened at $0.34 on Friday. The company has a market cap of $7.94 million, a P/E ratio of -0.11 and a beta of 1.19. The firm has a fifty day moving average price of $0.35 and a 200 day moving average price of $0.41. Turnstone Biologics Corp. has a 12 month low of $0.29 and a 12 month high of $3.05.

Turnstone Biologics (NASDAQ:TSBX) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.25). On average, equities analysts forecast that Turnstone Biologics Corp. will post -3.32 EPS for the current year.

Turnstone Biologics Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.